Can anyone inject liraglutide for weight loss? Not quite

What did @dr.dorado actually say?

Honestly, this is a tough one to fact-check in the traditional sense. The transcript provided appears to be a machine-translation artifact, likely a garbled auto-caption of a Spanish-language video. What comes through is largely incoherent in English, referencing vague statements about "the state," "the organization," and percentages that don't connect to any coherent medical claim.

The caption, however, is clear: "Can anyone who wants to lose weight inject liraglutide?" That's the core question this video is presumably answering. Based on the hashtags and the platform context, @dr.dorado appears to be a Spanish-speaking physician discussing who qualifies for Saxenda (liraglutide) for weight loss. Without a reliable transcript, we're fact-checking the question posed, not a specific answer given.

Does the science back up the premise?

No, not everyone who wants to lose weight qualifies for liraglutide. The FDA approval criteria are specific, and the clinical trial data was built around a defined population. This isn't a drug you self-select into.

Liraglutide 3.0 mg (Saxenda) was approved by the FDA in 2014 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The pivotal approval trial, the SCALE Obesity and Prediabetes study (Pi-Sunyer et al., 2015, New England Journal of Medicine), showed a mean weight loss of 8.4% versus 2.5% for placebo over 56 weeks. That's a real effect, but it was studied in a specific population, not in people who simply want to drop a few pounds before a vacation.

There are also contraindications that aren't minor. A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 (MEN2), is a hard stop. Pancreatitis history is another red flag. These aren't footnotes. They're reasons a prescriber needs to evaluate someone before writing this prescription.

What did they get wrong, or right?

We can't fully credit or fault @dr.dorado's specific statements because the transcript is unreliable. But we can assess the question the video raises, and the answer the medical evidence gives is nuanced.

If the creator is telling viewers that liraglutide is not for everyone, that's correct. If they're implying anyone motivated enough can access it, that's a problem. Liraglutide is a prescription medication regulated by the FDA. It requires a clinical evaluation, a documented BMI threshold or comorbidity, and an ongoing prescriber relationship to monitor for adverse effects including tachycardia, nausea, gallbladder disease, and the thyroid concerns flagged in animal studies.

What concerns us about the framing of this video, regardless of what was actually said, is the environment it exists in. TikTok GLP-1 content frequently blurs the line between education and instruction. A 414,900-view video asking "can anyone inject liraglutide?" carries real public health weight. The answer needs to be clearly "no, not without proper clinical screening," not implied or buried in caveats.

What should you actually know?

Liraglutide works. The evidence for weight loss in eligible patients is solid. But eligibility matters enormously, and self-administering a GLP-1 agonist without medical oversight is not a safe workaround.

The SCALE program across multiple trials consistently showed meaningful weight reduction in patients meeting BMI criteria, with additional cardiovascular and glycemic benefits in some populations (Davies et al., 2015, The Lancet). However, dropout rates due to gastrointestinal side effects were significant, and the drug requires titration over several weeks to reach the therapeutic 3.0 mg dose. Skipping that process because someone got the drug without a prescription is how people end up in urgent care with severe nausea and dehydration.

It's also worth knowing that liraglutide is not the same as semaglutide. They're both GLP-1 receptor agonists, but semaglutide has shown greater weight loss efficacy in head-to-head data (Rubino et al., 2022, JAMA). Compounded versions of these drugs are not equivalent to FDA-approved branded products. If you're exploring GLP-1 therapy for weight management, that conversation starts with a licensed clinician reviewing your full health history, not a TikTok video.

Bottom line on this video

The question posed is legitimate and worth answering publicly. The answer is no, not everyone qualifies, and that's not a bureaucratic technicality. It's a clinical reality tied to real safety data. We can't assess how well @dr.dorado answered it based on the transcript available, but the public health stakes of getting this wrong on a platform with 400,000 views are real enough to say it plainly here.